Trabectedin (NCT07076186)

Name: Trabectedin trial for Uterine Leiomyosarcoma (NCT07076186)
Uploaded: 2026-10-31T14:54:14.082Z
Duration: 1 min 23 s
Description: Trabectedin trial for Uterine Leiomyosarcoma (NCT07076186). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07076186.

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS: a one-minute explainerNCT070761861 min

Trabectedin trial for Uterine Leiomyosarcoma (NCT07076186). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult women with stage IB–III uterine leiomyosarcoma fully removed by surgery, including hysterectomy. There must be no residual disease, no prior chemotherapy for this cancer and no previous pelvic radiation.

The idea: test six cycles of doxorubicin and trabectedin infusions after surgery. Both disrupt DNA processes needed for cell survival and division. Treatment must begin within three months of surgery. Researchers track recurrence, survival, toxicity and quality of life, and assess decentralized care.

This phase 2 study plans 48 patients. Elise Nassif Haddad leads MD Anderson’s recruiting Houston site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.